Barclays has initiated coverage on Amneal Pharmaceuticals Inc (AMRX) with an Overweight rating. This marks the firm's first assessment of the company's investment potential based on its research and analysis of the pharmaceuticals industry and Amneal's growth prospects.
Amneal Pharmaceuticals, headquartered in Bridgewater, New Jersey, operates in the pharmaceuticals sector and employs approximately 8,100 full-time staff. The company offers a diverse range of products, including over 280 product families across various dosage forms through its Affordable Medicines segment. Its Specialty segment focuses on branded pharmaceuticals for central nervous system disorders, while the AvKARE segment provides products and services primarily to governmental agencies.
As of December 8, 2025, Amneal's stock is priced at $12.35, with a market capitalization of $3.6 billion. The company reported a trailing twelve months (TTM) price-to-earnings (P/E) ratio of 1,058.10 and earnings per share (EPS) of $0.01.
Upcoming earnings are scheduled for August 3, 2026, with an estimated EPS of $0.22 and revenue of $783.1 million. This follows a series of recent earnings surprises, including Q3 2025, where EPS was $0.17 against an estimate of $0.14, representing a 21.2% surprise.
Analyst consensus as of December 1, 2025, includes 2 Strong Buy, 7 Buy, 1 Hold, and no Sell ratings, with an overall consensus rating of Buy. The move underscores Barclays' confidence in Amneal's strategic positioning within the pharmaceuticals market.